One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: Results from the DiabEtic Argentina Registry (DEAR)

Late clinical outcomes for SeQuent please paclitaxel‐coated balloons in PCI of instent restenosis and de novo lesions: A single‐center, real world registry

“…A key feature of PCB is the ability to revascularize and medicate vessels, without deploying an endoluminal scaffold . Several small registries and few randomized trials, have reported favourable angiographic and clinical outcomes for drug‐coated balloons in the treatment of ISR and DNL . For treatment of ISR, PCB appears to have superior efficacy compared to both plain balloon angioplasty, and is noninferior to BMS .…”

Drug-coated balloon in combination with bare metal stent strategy for de novo coronary artery disease

“…Recent evidences support using paclitaxel drug-coated balloon (DCB) catheters as a therapeutic method for de novo coronary lesions, [1,2] in-stent restenosis (ISR), [2,3] small coronary vessels, [4,5] and coronary bifurcation lesions. [6,7] DCB was designed to achieve comparable efficacy in neointimal proliferation through local drug delivery without requiring foreign body implantation or prolonged dual antiplatelet therapy (DAPT).…”

Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: A randomized trial

“…Among the many limitations of this study, however, are the lack of adjustment for potential confouders and the low overall differences between groups in terms of revascularization. 24 The recent drug-eluting balloon in acute ST-elevation MI DEB-AMI compared the Dior PEB plus BMS vs BMS vs DES in primary PCI. 25 In this study, predilatation with PEB did not reduce restenosis compared with BMS.…”